Senseonics, Incorporated
Creators of the first and only long-term implantable CGM
Creators of the first and only long-term implantable CGM
Senseonics, Incorporated is a medical device startup company based in Germantown, Maryland, USA, near Washington, DC. Since its founding in 1996, the company has been dedicated to developing transformative glucose monitoring products for people with diabetes. Their flagship product is the first and only long-term implantable continuous glucose monitoring (CGM) system. This innovative system, which incorporates breakthrough fluorescence sensing technology, consists of a small sensor implanted under the skin, an external transmitter, and a mobile medical application. It enables discreet and easy access to real-time glucose measurements without the need for a dedicated receiver. Senseonics recently received a significant investment of $50.00M in Post-IPO Debt from Hercules Capital on 11 September 2023, signaling confidence in the company's technology and market potential within the biotechnology and healthcare industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $50.00M | 1 |
|
11 Sep 2023 |
| Post-IPO Equity | $50.00M | - | 18 Jan 2021 | |
| Post-IPO Equity | $45.00M | 2 |
|
10 Aug 2020 |
| Post-IPO Debt | $35.00M | 1 |
|
10 Aug 2020 |
| Post-IPO Debt | $45.00M | - | 01 Jan 2019 |
No recent news or press coverage available for Senseonics, Incorporated.
We care about your data, and we'd love to use cookies make your experience better.
